These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 20943046

  • 21. Treatment of erythrodermic psoriasis with etanercept.
    Esposito M, Mazzotta A, de Felice C, Papoutsaki M, Chimenti S.
    Br J Dermatol; 2006 Jul; 155(1):156-9. PubMed ID: 16792768
    [Abstract] [Full Text] [Related]

  • 22. Etanercept treatment for children and adolescents with plaque psoriasis.
    Paller AS, Siegfried EC, Langley RG, Gottlieb AB, Pariser D, Landells I, Hebert AA, Eichenfield LF, Patel V, Creamer K, Jahreis A, Etanercept Pediatric Psoriasis Study Group.
    N Engl J Med; 2008 Jan 17; 358(3):241-51. PubMed ID: 18199863
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Th1, Th2, Th17 and regulatory T cell pattern in psoriatic patients: modulation of cytokines and gene targets induced by etanercept treatment and correlation with clinical response.
    Quaglino P, Bergallo M, Ponti R, Barberio E, Cicchelli S, Buffa E, Comessatti A, Costa C, Terlizzi ME, Astegiano S, Novelli M, Cavallo R, Bernengo MG.
    Dermatology; 2011 Jan 17; 223(1):57-67. PubMed ID: 21865674
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Response of the clinically uninvolved skin of psoriatic patients to tape stripping during acitretin treatment.
    Gerritsen MJ, van Pelt JP, van de Kerkhof PC.
    Acta Derm Venereol; 1996 Jan 17; 76(1):6-9. PubMed ID: 8721480
    [Abstract] [Full Text] [Related]

  • 29. Serum concentrations of interleukin-2 and tumour necrosis factor-α under cyclosporine versus acitretin treatment in plaque-type psoriasis.
    Akçali C, Guven EH, Kirtak N, Inaloz HS, Ozgoztasi O, Guvenc U.
    J Int Med Res; 2014 Oct 17; 42(5):1118-22. PubMed ID: 25143337
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
    Van Lümig PP, Lecluse LL, Driessen RJ, Spuls PI, Boezeman JB, van de Kerkhof PC, De Jong EM.
    Br J Dermatol; 2010 Oct 17; 163(4):838-46. PubMed ID: 20649798
    [Abstract] [Full Text] [Related]

  • 32. Etanercept: efficacy and safety.
    Jiménez-Puya R, Gómez-García F, Amorrich-Campos V, Moreno-Giménez JC.
    J Eur Acad Dermatol Venereol; 2009 Apr 17; 23(4):402-5. PubMed ID: 19210697
    [Abstract] [Full Text] [Related]

  • 33. CTACK /CCL27 expression in psoriatic skin and its modification after administration of etanercept.
    Campanati A, Goteri G, Simonetti O, Ganzetti G, Giuliodori K, Stramazzotti D, Morichetti D, Bernardini ML, Mannello B, Fabris G, Offidani A.
    Br J Dermatol; 2007 Dec 17; 157(6):1155-60. PubMed ID: 17916208
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.
    Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, Guzzo C, Xia Y, Zhou B, Li S, Dooley LT, Goldstein NH, Menter A, ACCEPT Study Group.
    N Engl J Med; 2010 Jan 14; 362(2):118-28. PubMed ID: 20071701
    [Abstract] [Full Text] [Related]

  • 38. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.
    Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, Zitnik R, van de Kerkhof PC, Melvin L, Etanercept Psoriasis Study Group.
    Br J Dermatol; 2005 Jun 14; 152(6):1304-12. PubMed ID: 15948997
    [Abstract] [Full Text] [Related]

  • 39. Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept.
    Lizzul PF, Aphale A, Malaviya R, Sun Y, Masud S, Dombrovskiy V, Gottlieb AB.
    J Invest Dermatol; 2005 Jun 14; 124(6):1275-83. PubMed ID: 15955104
    [Abstract] [Full Text] [Related]

  • 40. Treatment with 311-nm ultraviolet B accelerates and improves the clearance of psoriatic lesions in patients treated with etanercept.
    Wolf P, Hofer A, Legat FJ, Bretterklieber A, Weger W, Salmhofer W, Kerl H.
    Br J Dermatol; 2009 Jan 14; 160(1):186-9. PubMed ID: 19067710
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.